Back to results
US 2019/0240197 A1Published application
Pharmaceutical compositions for treating cystic fibrosis
AssigneeVertex Pharmaceuticals Incorporated
InventorsCathy Chu, Varsha Dhamankar, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz, Weichao George Chen
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
Claims13
A pharmaceutical composition comprising
- (a) 15 mg to 250 mg of Compound I:
- (b) a first solid dispersion comprising 10 mg to 150 mg of Compound II:
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion;
- and
- (c) a second solid dispersion comprising 25 mg to 200 mg of Compound III:
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion.
3 more elements
A pharmaceutical composition comprising:
- (a) 10 wt % to 30 wt % of Compound I:
- relative to the total weight of the pharmaceutical composition;
- (b) 8 wt % to 30 wt % of a first solid dispersion relative to the total weight of the pharmaceutical composition,
- wherein the first solid dispersion comprises 70 wt % to 90 wt % of Compound II relative to the total weight of the first solid dispersion:
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion;
- and
- (c) 10 wt % to 45 wt % of a second solid dispersion relative to the total weight of the pharmaceutical composition;
- wherein the second solid dispersion comprises 70 wt % to 90 wt % of Compound III relative to the total weight of the second solid dispersion:
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion.
6 more elements
A single tablet comprising:
- (a) 25 mg to 125 mg of Compound I:
- (b) 60 mg to 65 mg of a first solid dispersion comprising 80 wt % Compound II relative to the total weight of the first solid dispersion:
- and 20 wt % of a hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion;
- and
- (c) 90 mg to 95 mg, or 180 mg to 190 mg of a second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion:
- 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion;
- and 19.5 wt % of a hydroxypropyl methylcellulose acetate succinate to the total weight of the second solid dispersion
- (d) 85 mg to 275 mg of microcrystalline cellulose;
- (e) 10 mg to 35 mg of croscarmellose sodium;
- and
- (f) 2 mg to 7 mg of magnesium stearate.
8 more elements
A pharmaceutical composition comprising
- (a) 12 wt % to 30 wt % Compound I relative to the total weight of the pharmaceutical composition:
- (b) 5 wt % to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:
- (c) 10 wt % to 25 wt % of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition:
- (d) 20 wt % to 45 wt % of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;
- (e) 3 wt %-8 wt % of croscarmellose sodium relative to the total weight of the pharmaceutical composition;
- and
- (f) 0.5 wt % to 2 wt % of magnesium stearate relative to the total weight of the pharmaceutical composition.
4 more elements
Dependencies are inferred from the claim text.